Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
canakinumab + spartalizumab + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a four-drug combination regimen consisting of canakinumab, spartalizumab, nab-paclitaxel, and gemcitabine. Canakinumab (ACZ885, brand name Ilaris) is a high-affinity human monoclonal antibody targeting interleukin-1β (IL-1β), thereby reducing inflammation. Spartalizumab (PDR001) is a monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor on T cells to enhance anti-tumor immune responses. Nab-paclitaxel (brand name Abraxane) is an albumin-bound formulation of paclitaxel that inhibits microtubule disassembly, disrupting cell division. Gemcitabine is a nucleoside analog that interferes with DNA synthesis and induces apoptosis in rapidly dividing cells. This quadruplet regimen has been investigated in phase 1b/2 clinical trials for metastatic pancreatic cancer to determine safety and tolerability; it combines immunotherapy with standard chemotherapy[1][3][4][5][8].
- Other names
- canakinumab + spartalizumab + nab-paclitaxel + gemcitabine
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA polymerase familyIL1B (Interleukin-1 beta)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on canakinumab + spartalizumab + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on canakinumab + spartalizumab + nab-paclitaxel + gemcitabine.